Watch ASCO president Dr. Clifford Hudis discuss 2014 Annual meeting theme: Science and Society
There are just a few days to go before the ASCO general meeting gets under way in Chicago, with this year’s theme being “Science and Society”. 2014 represents a golden anniversary for ASCO, as it is now the 50th year of its continued support and advocacy of the continued development of oncological science for society.
A traditional gift for a 50th anniversary is gold, and ASCO has once again delivered a wealth of important information, over 5000 abstracts released this year, each selected for its relevance to continuing the advance in cancer research and improvements in patient care.
The Branding Science Group has been around for a quarter of that time and has continuously supported the creation and development of Oncology brands. For this reason, we will be paying particular attention to discussions around;
- New developments amongst targeted therapies - In particular those relating to Breast Cancer, Chronic Lymphocytic Leukaemia and Non-Small Cell Lung Cancer. These indications are all facing significant change with multiple new market entrants bringing increased hope for patients, but potential headaches for prescribing physicians and payers.
- Progress in immunotherapy - conceptually one of the most exciting areas of Oncology (working with your own immune system to fight malignancies) as well as one with real momentum and a highly anticipated future development pipeline.
- Improving patient care and quality of life – remembering that ASCO is not all about the Science, it’s about improving patient lives and end of life care. Here there are a number of interesting studies evaluating how lower intensity treatment regimens or a greater focus on palliation can improve the survival vs. QoL balance for patients and their carers.
We hope that you also enjoy ASCO 2014 and would be delighted to hear your thoughts on this golden year. What are you most looking forward to? What do you think will be the most interesting discussion this year? Which new data will especially change patient outcomes for the better?
Written by Joe Gadilhe, Director at Branding Science